Get Our FREE Newsletter

Sign Up

3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug

Spread the love

The Alzheimer’s disease (“AD”) market finally saw a ray of hope as the FDA granted accelerated approval to Biogen BIIB and Japan-based partner, Eisai’s Alzheimer’s drug, Aduhelm (aducanumab)on Jun 7. Aduhelm, a monoclonal antibody treatment, has been approved to

This post was originally published on this site